<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36556422</PMID><DateRevised><Year>2022</Year><Month>12</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-1729</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>08</Day></PubDate></JournalIssue><Title>Life (Basel, Switzerland)</Title><ISOAbbreviation>Life (Basel)</ISOAbbreviation></Journal><ArticleTitle>Effect of Vaccination against SARS-CoV-2 on Long COVID-19: A Narrative Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2057</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/life12122057</ELocationID><Abstract><AbstractText>Vaccines against SARS-CoV-2 have saved millions of lives and played an important role in containing the COVID-19 pandemic. Vaccination against SARS-CoV-2 is also associated with reduced disease severity and, perhaps, with COVID-19 symptom burden. In this narrative review, we present, in a clinically relevant question-and-answer manner, the evidence regarding the association between vaccination against SARS-CoV-2 and long COVID-19. We discuss how the mechanism of action of vaccines could interplay with the pathophysiology of post-COVID-19 condition. Furthermore, we describe how specific factors, such as the number of vaccine doses and the type of SARS-CoV-2 variants, may affect post-COVID-19 condition. We also discuss the role of timing for vaccination in relation to the onset of long COVID-19 symptoms, as it seems to affect the frequency and severity of the condition. Additionally, we describe the potential modifying effect of age, as well as the association of type and level of immune response with long COVID-19. We also describe how system-specific long COVID-19 sequelae, namely neurocognitive-psychologic symptoms and cardiovascular pathology, could be altered by vaccination. Last, we address the question of whether seasonal influenza vaccination has a meaningful impact on the frequency of long COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tofarides</LastName><ForeName>Andreas G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Nicosia General Hospital, Nicosia 2029, Cyprus.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, 451 10 Ioannina, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christaki</LastName><ForeName>Eirini</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, 451 10 Ioannina, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milionis</LastName><ForeName>Haralampos</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3958-2266</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, 451 10 Ioannina, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nikolopoulos</LastName><ForeName>Georgios K</ForeName><Initials>GK</Initials><Identifier Source="ORCID">0000-0002-3307-0246</Identifier><AffiliationInfo><Affiliation>Medical School, University of Cyprus, Nicosia 2029, Cyprus.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Life (Basel)</MedlineTA><NlmUniqueID>101580444</NlmUniqueID><ISSNLinking>2075-1729</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 vaccination</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 vaccines</Keyword><Keyword MajorTopicYN="N">immunity</Keyword><Keyword MajorTopicYN="N">long COVID-19</Keyword><Keyword MajorTopicYN="N">post-COVID-19 condition</Keyword><Keyword MajorTopicYN="N">post-COVID-19 sequelae</Keyword><Keyword MajorTopicYN="N">variant</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>23</Day><Hour>1</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36556422</ArticleId><ArticleId IdType="pmc">PMC9785763</ArticleId><ArticleId IdType="doi">10.3390/life12122057</ArticleId><ArticleId IdType="pii">life12122057</ArticleId></ArticleIdList><ReferenceList><Reference><Citation> [(accessed on 11 November 2022)].  Available online:  worldometers.info/coronavirus.</Citation></Reference><Reference><Citation>World Health Organization  Director-General&#x2019;s remarks at the Media Briefing on 2019-nCoV on 11 February 2020. 2020.  [(accessed on 11 November 2022)].  Available online:  http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020.</Citation></Reference><Reference><Citation>Wang H., Paulson K.R., Pease S.A., Watson S., Comfort H., Zheng P., Aravkin A.Y., Bisignano C., Barber R.M., Alam T., et al. Estimating excess mortality due to the COVID-19 pandemic: A systematic analysis of COVID-19-related mortality, 2020&#x2013;21. Lancet. 2022;399:1513&#x2013;1536. doi: 10.1016/S0140-6736(21)02796-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02796-3</ArticleId><ArticleId IdType="pmc">PMC8912932</ArticleId><ArticleId IdType="pubmed">35279232</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal M., Omirah M.A., Hussein A., Saeed H. Assessment and characterisation of post-COVID-19 manifestations. Int. J. Clin. Pract. 2021;75:e13746. doi: 10.1111/ijcp.13746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.13746</ArticleId><ArticleId IdType="pmc">PMC7536922</ArticleId><ArticleId IdType="pubmed">32991035</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang F., Deng L., Zhang L., Cai Y., Cheung C.W., Xia Z. Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) J. Gen. Intern. Med. 2020;35:1545&#x2013;1549. doi: 10.1007/s11606-020-05762-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-020-05762-w</ArticleId><ArticleId IdType="pmc">PMC7088708</ArticleId><ArticleId IdType="pubmed">32133578</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A., Bernabei R., Landi F. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324:603. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Barman M.P., Rahman T., Bora K., Borgohain C. COVID-19 pandemic and its recovery time of patients in India: A pilot study. Diabetes Metab. Syndr. Clin. Res. Rev. 2020;14:1205&#x2013;1211. doi: 10.1016/j.dsx.2020.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.07.004</ArticleId><ArticleId IdType="pmc">PMC7343664</ArticleId><ArticleId IdType="pubmed">32673841</ArticleId></ArticleIdList></Reference><Reference><Citation>Prescott H.C., Angus D.C. Enhancing Recovery from Sepsis. JAMA. 2018;319:62. doi: 10.1001/jama.2017.17687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.17687</ArticleId><ArticleId IdType="pmc">PMC5839473</ArticleId><ArticleId IdType="pubmed">29297082</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Q., Xu M., Li J., Liu Y., Zhalng J., Xu Y., Dong W. Clinical sequelae of COVID-19 survivors in Wuhan, China: A single-centre longitudinal study. Clin. Microbiol. Infect. 2021;27:89&#x2013;95. doi: 10.1016/j.cmi.2020.09.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.09.023</ArticleId><ArticleId IdType="pmc">PMC7510771</ArticleId><ArticleId IdType="pubmed">32979574</ArticleId></ArticleIdList></Reference><Reference><Citation>Go&#xeb;rtz Y.M.J., Van Herck M., Delbressine J.M., Vaes A.W., Meys R., Machado F.V.C., Houben-Wilke S., Burtin C., Posthuma R., Franssen F.M.E., et al. Franssen Persistent symptoms 3&#x2005;months after a SARS-CoV-2 infection: The post-COVID-19 syndrome? ERJ Open Res. 2020;6:00542&#x2013;02020. doi: 10.1183/23120541.00542-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00542-2020</ArticleId><ArticleId IdType="pmc">PMC7491255</ArticleId><ArticleId IdType="pubmed">33257910</ArticleId></ArticleIdList></Reference><Reference><Citation>Evaluating and Caring for Patients with Post-COVID Conditions: Interim Guidance.  [(accessed on 15 June 2021)]; Available online:  https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-index.html.</Citation></Reference><Reference><Citation>Word Organization Health (WHO)  A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus, 6 October 2021; WHO. 2021.  [(accessed on 15 October 2021)].  Available online:  https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1.</Citation></Reference><Reference><Citation>Oakes B., Hoagland-Henefield M., Komaroff A.L., Erickson J.L., Huber B.T. Human Endogenous Retrovirus-K18 Superantigen Expression and Human Herpesvirus-6 and Human Herpesvirus-7 Viral Loads in Chronic Fatigue Patients. Clin. Infect. Dis. 2013;56:1394&#x2013;1400. doi: 10.1093/cid/cit086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cit086</ArticleId><ArticleId IdType="pubmed">23408682</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickie I., Davenport T., Wakefield D., Vollmer-Conna U., Cameron B., Vernon S.D., Reeves W.C., Lloyd A. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: Prospective cohort study. BMJ. 2006;333:575. doi: 10.1136/bmj.38933.585764.AE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.38933.585764.AE</ArticleId><ArticleId IdType="pmc">PMC1569956</ArticleId><ArticleId IdType="pubmed">16950834</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyle P.K., Krupp L.B., Doscher C., Amin K. Borrelia burgdorferi Reactivity in Patients with Severe Persistent Fatigue Who Are from a Region in Which Lyme Disease Is Endemic. Clin. Infect. Dis. 1994;18((Suppl. 1)):S24&#x2013;S27. doi: 10.1093/clinids/18.Supplement_1.S24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/clinids/18.Supplement_1.S24</ArticleId><ArticleId IdType="pubmed">8148448</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control . Prevalence of Post COVID-19 Condition Symptoms: A Systematic Review and Meta-Analysis of Cohort Study Data Stratified by Recruitment Setting. ECDC; Stockholm, Sweden: 2022.</Citation></Reference><Reference><Citation>Alkodaymi M.S., Omrani O.A., Fawzy N.A., Shaar B.A., Almamlouk R., Riaz M., Obeidat M., Obeidat Y., Gerberi D., Taha R.M., et al. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: A systematic review and meta-analysis. Clin. Microbiol. Infect. 2022;28:657&#x2013;666. doi: 10.1016/j.cmi.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8812092</ArticleId><ArticleId IdType="pubmed">35124265</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik P., Patel K., Pinto C., Jaiswal R., Tirupathi R., Pillai S., Patel U. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)&#x2014;A systematic review and meta-analysis. J. Med. Virol. 2022;94:253&#x2013;262. doi: 10.1002/jmv.27309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27309</ArticleId><ArticleId IdType="pmc">PMC8662132</ArticleId><ArticleId IdType="pubmed">34463956</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M., Manoharan L., Elkheir N., Cheng V., Dagens A., Hastie C., O&#x2019;Hara M., Suett J., Dahmash D., Bugaeva P., et al. Characterising long COVID: A living systematic review. BMJ Glob. Health. 2021;6:e005427. doi: 10.1136/bmjgh-2021-005427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-005427</ArticleId><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-P&#xe9;rez O., Merino E., Leon-Ramirez J.-M., Andres M., Ramos J.M., Arenas-Jim&#xe9;nez J., Asensio S., Sanchez R., Ruiz-Torregrosa P., Galan I., et al. Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study. J. Infect. 2021;82:378&#x2013;383. doi: 10.1016/j.jinf.2021.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.01.004</ArticleId><ArticleId IdType="pmc">PMC7802523</ArticleId><ArticleId IdType="pubmed">33450302</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Burden of Disease Long COVID Collaborators. Hanson S.W., Abbafati C., Aerts J.G., Al-Aly Z., Ashbaugh C., Ballouz T., Blyuss O., Bobkova P., Bonsel G. Estimated Global Proportions of Individuals with Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328:1604. doi: 10.1001/jama.2022.18931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.18931</ArticleId><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M., Pujol J.C., Spector T.D., Ourselin S., Steves C.J. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022;399:2263&#x2013;2264. doi: 10.1016/S0140-6736(22)00941-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00941-2</ArticleId><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Arjun M.C., Singh A.K., Roy P., Ravichandran M., Mandal S., Pal D., Das K., Gajjala A., Venkateshan M., Mishra B., et al. Long COVID following Omicron wave in Eastern India&#x2014;A retrospective cohort study. J. Med Virol. 2022;1002:36224705. doi: 10.1002/jmv.28214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28214</ArticleId><ArticleId IdType="pmc">PMC9874641</ArticleId><ArticleId IdType="pubmed">36224705</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis R.H., Santillana M., Ognyanova K., Safarpour A., Trujillo K.L., Simonson M.D., Green J., Quintana A., Druckman J., Baum M.A., et al. Prevalence and Correlates of Long COVID Symptoms among US Adults. JAMA Netw. Open. 2022;5:e2238804. doi: 10.1001/jamanetworkopen.2022.38804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.38804</ArticleId><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson O.J., Barnsley G., Toor J., Hogan A.B., Winskill P., Ghani A.C. Global impact of the first year of COVID-19 vaccination: A mathematical modelling study. Lancet Infect. Dis. 2022;22:1293&#x2013;1302. doi: 10.1016/S1473-3099(22)00320-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00320-6</ArticleId><ArticleId IdType="pmc">PMC9225255</ArticleId><ArticleId IdType="pubmed">35753318</ArticleId></ArticleIdList></Reference><Reference><Citation>Feikin D.R., Higdon M.M., Abu-Raddad L.J., Andrews N., Araos R., Goldberg Y., Groome M.J., Huppert A., O&#x2019;Brien K.L., Smith P.G., et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: Results of a systematic review and meta-regression. Lancet. 2022;399:924&#x2013;944. doi: 10.1016/S0140-6736(22)00152-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00152-0</ArticleId><ArticleId IdType="pmc">PMC8863502</ArticleId><ArticleId IdType="pubmed">35202601</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephenson J. US COVID-19 Vaccination Efforts May Have Prevented More than 1 Million Deaths, 10 Million Hospitalizations. JAMA Health. Forum. 2021;2:e215118. doi: 10.1001/jamahealthforum.2021.5118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamahealthforum.2021.5118</ArticleId><ArticleId IdType="pubmed">36218918</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele M.K., Couture A., Reed C., Iuliano D., Whitaker M., Fast H., Hall A.J., MacNeil A., Cadwell B., Marks K.J., et al. Estimated Number of COVID-19 Infections, Hospitalizations, and Deaths Prevented among Vaccinated Persons in the US, December 2020 to September 2021. JAMA Netw. Open. 2022;5:e2220385. doi: 10.1001/jamanetworkopen.2022.20385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.20385</ArticleId><ArticleId IdType="pmc">PMC9260489</ArticleId><ArticleId IdType="pubmed">35793085</ArticleId></ArticleIdList></Reference><Reference><Citation>Havers F.P., Pham H., Taylor C.A., Whitaker M., Patel K., Anglin O., Kambhampati A.K., Milucky J., Zell E., Moline H.L., et al. COVID-19-Associated Hospitalizations among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022. JAMA Intern. Med. 2022;182:1071. doi: 10.1001/jamainternmed.2022.4299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2022.4299</ArticleId><ArticleId IdType="pmc">PMC9459904</ArticleId><ArticleId IdType="pubmed">36074486</ArticleId></ArticleIdList></Reference><Reference><Citation>McNamara L.A., Wiegand R.E., Burke R.M., Sharma A.J., Sheppard M., Adjemian J., Ahmad F.B., Anderson R.N., Barbour K.E., Binder A.M., et al. Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: An ecological analysis of national surveillance data. Lancet. 2021;399:152&#x2013;160. doi: 10.1016/S0140-6736(21)02226-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02226-1</ArticleId><ArticleId IdType="pmc">PMC8565933</ArticleId><ArticleId IdType="pubmed">34741818</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph G., Barnes J., Azziz-Baumgartner E., Arvay M., Fry A., Hall A., Kutty P., MacNeil A., Donald L.C., Reynolds S., et al. Association of mRNA Vaccination with Clinical and Virologic Features of COVID-19 among US Essential and Frontline Workers. JAMA. 2022;328:1523&#x2013;1533. doi: 10.1001/jama.2022.18550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.18550</ArticleId><ArticleId IdType="pmc">PMC9579910</ArticleId><ArticleId IdType="pubmed">36255426</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews N., Tessier E., Stowe J., Gower C., Kirsebom F., Simmons R., Gallagher E., Thelwall S., Groves N., Dabrera G., et al. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. N. Engl. J. Med. 2022;386:340&#x2013;350. doi: 10.1056/NEJMoa2115481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2115481</ArticleId><ArticleId IdType="pmc">PMC8781262</ArticleId><ArticleId IdType="pubmed">35021002</ArticleId></ArticleIdList></Reference><Reference><Citation>Laake I., Skodvin S.N., Blix K., Caspersen I.H., Gjessing H.K., Juvet L.K., Magnus P., Mjaaland S., Robertson A.H., Starrfelt J., et al. Effectiveness of mRNA booster vaccination against mild, moderate, and severe COVID-19 caused by the Omicron variant in a large, population-based, Norwegian cohort. J. Infect. Dis. 2022;226:1924&#x2013;1933. doi: 10.1093/infdis/jiac419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac419</ArticleId><ArticleId IdType="pmc">PMC9620770</ArticleId><ArticleId IdType="pubmed">36259543</ArticleId></ArticleIdList></Reference><Reference><Citation>Barouch D.H. Covid-19 Vaccines&#x2014;Immunity, Variants, Boosters. N. Engl. J. Med. 2022;387:1011&#x2013;1020. doi: 10.1056/NEJMra2206573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra2206573</ArticleId><ArticleId IdType="pmc">PMC9454645</ArticleId><ArticleId IdType="pubmed">36044620</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferdinands J.M., Rao S., Dixon B.E., Mitchell P.K., DeSilva M.B., Irving S.A., Lewis N., Natarajan K., Stenehjem E., Grannis S.J., et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19&#x2013;Associated Emergency Department and Urgent Care Encounters and Hospitalizations among Adults during Periods of Delta and Omicron Variant Predominance&#x2014;VISION Network, 10 States, August 2021&#x2013;January 2022. MMWR Morb. Mortal. Wkly. Rep. 2022;71:255&#x2013;263. doi: 10.15585/mmwr.mm7107e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7107e2</ArticleId><ArticleId IdType="pmc">PMC8853475</ArticleId><ArticleId IdType="pubmed">35176007</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., P&#xe9;rez Marc G., Moreira E.D., Zerbini C., et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 2020;383:2603&#x2013;2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenck R.W., Jr., Klein N.P., Kitchin N., Gurtman A., Absalon J., Lockhart S., Perez J.L., Walter E.B., Senders S., Bailey R., et al. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N. Engl. J. Med. 2021;385:239&#x2013;250. doi: 10.1056/NEJMoa2107456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107456</ArticleId><ArticleId IdType="pmc">PMC8174030</ArticleId><ArticleId IdType="pubmed">34043894</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas S.J., Moreira E.D., Jr., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., P&#xe9;rez Marc G., Polack F.P., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N. Engl. J. Med. 2021;385:1761&#x2013;1773. doi: 10.1056/NEJMoa2110345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2110345</ArticleId><ArticleId IdType="pmc">PMC8461570</ArticleId><ArticleId IdType="pubmed">34525277</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannou B.G.N., Locke M.E.R., O&#x2019;Hare A.M., Bohnert A.S., Boyko E.J., Hynes M.D.M., Berry K. COVID-19 Vaccination Effectiveness Against Infection or Death in a National, U.S. Health Care System. Ann. Intern. Med. 2022;175:352&#x2013;361. doi: 10.7326/M21-3256.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-3256</ArticleId><ArticleId IdType="pmc">PMC8697485</ArticleId><ArticleId IdType="pubmed">34928700</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin D.-Y., Gu Y., Xu Y., Wheeler B., Young H., Sunny S.K., Moore Z., Zeng D. Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes. JAMA. 2022;328:1415. doi: 10.1001/jama.2022.17876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.17876</ArticleId><ArticleId IdType="pmc">PMC9513711</ArticleId><ArticleId IdType="pubmed">36155617</ArticleId></ArticleIdList></Reference><Reference><Citation>Centres for Disease Control and Prevention (CDC)  Safety of COVID-19 Vaccines.  [(accessed on 27 October 2022)]; Available online:  https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/safety-of-vaccines.html.</Citation></Reference><Reference><Citation>Gargano J.W., Wallace M., Hadler S.C., Langley G., Su J.R., Oster M.E., Broder K.R., Gee J., Weintraub E., Shimabukuro T., et al. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices&#x2014;United States, June 2021. MMWR. Morb. Mortal. Wkly. Rep. 2021;70:977&#x2013;982. doi: 10.15585/mmwr.mm7027e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7027e2</ArticleId><ArticleId IdType="pmc">PMC8312754</ArticleId><ArticleId IdType="pubmed">34237049</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz N.H., S&#xf8;rvoll I.H., Michelsen A.E., Munthe L.A., Lund-Johansen F., Ahlen M.T., Wiedmann M., Aamodt A.-H., Skatt&#xf8;r T.H., Tj&#xf8;nnfjord G.E., et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N. Engl. J. Med. 2021;384:2124&#x2013;2130. doi: 10.1056/NEJMoa2104882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2104882</ArticleId><ArticleId IdType="pmc">PMC8112568</ArticleId><ArticleId IdType="pubmed">33835768</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonnell E.P., Altomare N.J., Parekh Y.H., Gowda R.C., Parikh P.D., Lazar M.H., Blaser M.J. COVID-19 as a Trigger of Recurrent Guillain&#x2013;Barr&#xe9; Syndrome. Pathogens. 2020;9:965. doi: 10.3390/pathogens9110965.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens9110965</ArticleId><ArticleId IdType="pmc">PMC7699516</ArticleId><ArticleId IdType="pubmed">33228253</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Rumeileh S., Abdelhak A., Foschi M., Tumani H., Otto M. Guillain&#x2013;Barr&#xe9; syndrome spectrum associated with COVID-19: An up-to-date systematic review of 73 cases. J. Neurol. 2021;268:1133&#x2013;1170. doi: 10.1007/s00415-020-10124-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10124-x</ArticleId><ArticleId IdType="pmc">PMC7445716</ArticleId><ArticleId IdType="pubmed">32840686</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M., Penfold R.S., Merino J., Sudre C.H., Molteni E., Berry S., Canas L.S., Graham M.S., Klaser K., Modat M., et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: A prospective, community-based, nested, case-control study. Lancet Infect. Dis. 2022;22:43&#x2013;55. doi: 10.1016/S1473-3099(21)00460-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00460-6</ArticleId><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini E., Levi R., Sarti R., Pozzi C., Mollura M., Mantovani A., Rescigno M. Association between BNT162b2 Vaccination and Long COVID after Infections Not Requiring Hospitalization in Health Care Workers. JAMA. 2022;328:676. doi: 10.1001/jama.2022.11691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.11691</ArticleId><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Bowe B., Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat. Med. 2022;28:1461&#x2013;1467. doi: 10.1038/s41591-022-01840-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiersinga W.J., Rhodes A., Cheng A.C., Peacock S.J., Prescott H.C. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19) JAMA. 2020;324:782. doi: 10.1001/jama.2020.12839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12839</ArticleId><ArticleId IdType="pubmed">32648899</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg M., Maralakunte M., Garg S., Dhooria S., Sehgal I., Bhalla A.S., Vijayvergiya R., Grover S., Bhatia V., Jagia P., et al. The Conundrum of &#x2018;Long-COVID-19&#x2019;: A Narrative Review. Int. J. Gen. Med. 2021;14:2491&#x2013;2506. doi: 10.2147/IJGM.S316708.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJGM.S316708</ArticleId><ArticleId IdType="pmc">PMC8214209</ArticleId><ArticleId IdType="pubmed">34163217</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstock L.B., Brook J.B., Walters A.S., Goris A., Afrin L.B., Molderings G.J. Mast cell activation symptoms are prevalent in Long-COVID. Int. J. Infect. Dis. 2021;112:217&#x2013;226. doi: 10.1016/j.ijid.2021.09.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.09.043</ArticleId><ArticleId IdType="pmc">PMC8459548</ArticleId><ArticleId IdType="pubmed">34563706</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettini E., Locci M. SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. Vaccines. 2021;9:147. doi: 10.3390/vaccines9020147.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9020147</ArticleId><ArticleId IdType="pmc">PMC7918810</ArticleId><ArticleId IdType="pubmed">33673048</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J., Lu G., Tan S., Xia J., Xiong H., Yu X., Qi Q., Yu X., Li L., Yu H., et al. A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Res. 2020;30:936&#x2013;939. doi: 10.1038/s41422-020-00392-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-00392-7</ArticleId><ArticleId IdType="pmc">PMC7429369</ArticleId><ArticleId IdType="pubmed">32801356</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai W., Zhang X., Drelich A., Shi J., Hsu J.C., Luchsinger L., Hillyer C.D., Tseng C.-T.K., Jiang S., Du L. A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2. Cell Res. 2020;30:932&#x2013;935. doi: 10.1038/s41422-020-0387-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0387-5</ArticleId><ArticleId IdType="pmc">PMC7403570</ArticleId><ArticleId IdType="pubmed">32759966</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotty S. T Follicular Helper Cell Biology: A Decade of Discovery and Diseases. Immunity. 2019;50:1132&#x2013;1148. doi: 10.1016/j.immuni.2019.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.04.011</ArticleId><ArticleId IdType="pmc">PMC6532429</ArticleId><ArticleId IdType="pubmed">31117010</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayakumar B., Boustani K., Ogger P.P., Papadaki A., Tonkin J., Orton C.M., Ghai P., Suveizdyte K., Hewitt R.J., Desai S.R., et al. Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVID-19 respiratory disease. Immunity. 2022;55:542&#x2013;556. doi: 10.1016/j.immuni.2022.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2022.01.017</ArticleId><ArticleId IdType="pmc">PMC8789571</ArticleId><ArticleId IdType="pubmed">35151371</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuodi P., Gorelik Y., Zayyad H., Wertheim O., Wiegler K.B., Abu Jabal K., Dror A.A., Nazzal S., Glikman D., Edelstein M. Association between BNT162b2 vaccination and reported incidence of post-COVID-19 symptoms: Cross-sectional study 2020-21, Israel. NPJ Vaccines. 2022;7:101. doi: 10.1038/s41541-022-00526-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-022-00526-5</ArticleId><ArticleId IdType="pmc">PMC9411827</ArticleId><ArticleId IdType="pubmed">36028498</ArticleId></ArticleIdList></Reference><Reference><Citation>Peghin M., De Martino M., Palese A., Gerussi V., Bontempo G., Graziano E., Visintini E., D&#x2019;Elia D., Dellai F., Marrella F., et al. Post&#x2013;COVID-19 syndrome and humoral response association after 1 year in vaccinated and unvaccinated patients. Clin. Microbiol. Infect. 2022;28:1140&#x2013;1148. doi: 10.1016/j.cmi.2022.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.03.016</ArticleId><ArticleId IdType="pmc">PMC8940723</ArticleId><ArticleId IdType="pubmed">35339673</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon M.A., Luginbuhl R.D., Parker R. Reduced Incidence of Long-COVID Symptoms Related to Administration of COVID-19 Vaccines Both before COVID-19 Diagnosis and Up to 12 Weeks after. medRxiv. 2021 doi: 10.1101/2021.11.17.21263608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.11.17.21263608</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold D.T., Milne A., Samms E., Stadon L., Maskell N.A., Hamilton F.W. Symptoms After COVID-19 Vaccination in Patients with Persistent Symptoms After Acute Infection: A Case Series. Ann. Intern. Med. 2021;174:1334&#x2013;1336. doi: 10.7326/M21-1976.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-1976</ArticleId><ArticleId IdType="pmc">PMC8252827</ArticleId><ArticleId IdType="pubmed">34029484</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D., Bermingham C., Pouwels K.B., Glickman M., Nafilyan V., Zaccardi F., Khunti K., Alwan N.A., Walker A.S. Trajectory of long covid symptoms after covid-19 vaccination: Community based cohort study. BMJ. 2022;377:e069676. doi: 10.1136/bmj-2021-069676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-069676</ArticleId><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Strain W.D., Sherwood O., Banerjee A., van der Togt A., Hishmeh L., Rossman J. The Impact of COVID Vaccination on Symptoms of Long COVID: An International Survey of People with Lived Experience of Long COVID. Vaccines. 2022;10:652. doi: 10.3390/vaccines10050652.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10050652</ArticleId><ArticleId IdType="pmc">PMC9146071</ArticleId><ArticleId IdType="pubmed">35632408</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T., Knight M., A&#x2019;Court C., Buxton M., Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026. doi: 10.1136/bmj.m3026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3026</ArticleId><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institutes of Health (NIH)  NIH Launches New Initiative to Study &#x2018;Long COVID.  [(accessed on 11 November 2022)];2021  Available online:  https://www.nih.gov/about-nih/who-we-are/nih-director/statements/nih-launches-new-initiative-study-long-covid.</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence (UK)  COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19.  [(accessed on 11 November 2022)];2022  Available online:  https://pubmed.ncbi.nlm.nih.gov/33555768/</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Alwan N.A., Johnson L. Defining long COVID: Going back to the start. Med. 2021;2:501&#x2013;504. doi: 10.1016/j.medj.2021.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2021.03.003</ArticleId><ArticleId IdType="pmc">PMC7992371</ArticleId><ArticleId IdType="pubmed">33786465</ArticleId></ArticleIdList></Reference><Reference><Citation>British Society for Immunology  Long-Term Immunological Health Consequences of COVID-19 (British Society for Immunology, 2020) 2020.  [(accessed on 11 November 2022)].  Available online:  https://www.immunology.org/sites/default/fles/BSI_Briefng_Note_August_2020_FINAL.pdf.</Citation></Reference><Reference><Citation>di Toro A., Bozzani A., Tavazzi G., Urtis M., Giuliani L., Pizzoccheri R., Aliberti F., Fergnani V., Arbustini E. Long COVID: Long-term effects? Eur. Heart J. Suppl. 2021;23((Suppl. E)):E1&#x2013;E5. doi: 10.1093/eurheartj/suab080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/suab080</ArticleId><ArticleId IdType="pmc">PMC8503490</ArticleId><ArticleId IdType="pubmed">34650349</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Richards A., Barrasa M.I., Hughes S.H., Young R.A., Jaenisch R. Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues. Proc. Natl. Acad. Sci. USA. 2021;118:21. doi: 10.1073/pnas.2105968118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2105968118</ArticleId><ArticleId IdType="pmc">PMC8166107</ArticleId><ArticleId IdType="pubmed">33958444</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbasi J. Even Mild COVID-19 May Change the Brain. JAMA. 2022;327:1321. doi: 10.1001/jama.2022.4507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.4507</ArticleId><ArticleId IdType="pubmed">35319732</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittaker H.R., Gulea C., Koteci A., Kallis C., Morgan A.D., Iwundu C., Weeks M., Gupta R., Quint J.K. GP consultation rates for sequelae after acute covid-19 in patients managed in the community or hospital in the UK: Population based study. BMJ. 2021;375:e065834. doi: 10.1136/bmj-2021-065834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-065834</ArticleId><ArticleId IdType="pmc">PMC8715128</ArticleId><ArticleId IdType="pubmed">34965929</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisnivesky J.P., Govindarajulu U., Bagiella E., Goswami R., Kale M., Campbell K.N., Meliambro K., Chen Z., Aberg J.A., Lin J.J. Association of Vaccination with the Persistence of Post-COVID Symptoms. J. Gen. Intern. Med. 2022;37:1748&#x2013;1753. doi: 10.1007/s11606-022-07465-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-022-07465-w</ArticleId><ArticleId IdType="pmc">PMC8906626</ArticleId><ArticleId IdType="pubmed">35266128</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman B., Bluemke D.A., L&#xfc;scher T.F., Neubauer S. Long COVID: Post-acute sequelae of COVID-19 with a cardiovascular focus. Eur. Heart J. 2022;43:1157&#x2013;1172. doi: 10.1093/eurheartj/ehac031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehac031</ArticleId><ArticleId IdType="pmc">PMC8903393</ArticleId><ArticleId IdType="pubmed">35176758</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj S.R., Arnold A.C., Barboi A., Claydon V.E., Limberg J.K., Lucci V.-E.M., Numan M., Peltier A., Snapper H., Vernino S., et al. Long-COVID postural tachycardia syndrome: An American Autonomic Society statement. Clin. Auton. Res. 2021;31:365&#x2013;368. doi: 10.1007/s10286-021-00798-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10286-021-00798-2</ArticleId><ArticleId IdType="pmc">PMC7976723</ArticleId><ArticleId IdType="pubmed">33740207</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Xu E., Bowe B., Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat. Med. 2022;28:583&#x2013;590. doi: 10.1038/s41591-022-01689-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01689-3</ArticleId><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Puntmann V.O., Martin S., Shchendrygina A., Hoffmann J., Ka M.M., Giokoglu E., Vanchin B., Holm N., Karyou A., Laux G.S., et al. Long-term cardiac pathology in individuals with mild initial COVID-19 illness. Nat. Med. 2022;28:2117&#x2013;2123. doi: 10.1038/s41591-022-02000-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02000-0</ArticleId><ArticleId IdType="pmc">PMC9556300</ArticleId><ArticleId IdType="pubmed">36064600</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacek C., Karolina S., Orze&#x142; A., Fr&#x105;czek M., Tomasz Z. Comparison of the clinical differences between COVID-19, SARS, influenza, and the common cold: A systematic literature review. Adv. Clin. Exp. Med. 2021;30:109&#x2013;114. doi: 10.17219/acem/129573.</Citation><ArticleIdList><ArticleId IdType="doi">10.17219/acem/129573</ArticleId><ArticleId IdType="pubmed">33529514</ArticleId></ArticleIdList></Reference><Reference><Citation>Flerlage T., Boyd D.F., Meliopoulos V., Thomas P.G., Schultz-Cherry S. Influenza virus and SARS-CoV-2: Pathogenesis and host responses in the respiratory tract. Nat. Rev. Microbiol. 2021;19:425&#x2013;441. doi: 10.1038/s41579-021-00542-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00542-7</ArticleId><ArticleId IdType="pmc">PMC8023351</ArticleId><ArticleId IdType="pubmed">33824495</ArticleId></ArticleIdList></Reference><Reference><Citation>Musher D.M. Bacterial Coinfection in COVID-19 and Influenza Pneumonia. Am. J. Respir. Crit. Care Med. 2021;204:498&#x2013;500. doi: 10.1164/rccm.202106-1467ED.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202106-1467ED</ArticleId><ArticleId IdType="pmc">PMC8491255</ArticleId><ArticleId IdType="pubmed">34233146</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai Y., Tao X. Comparison of COVID-19 and influenza characteristics. J. Zhejiang Univ. Sci. B. 2021;22:87&#x2013;98. doi: 10.1631/jzus.B2000479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1631/jzus.B2000479</ArticleId><ArticleId IdType="pmc">PMC7885750</ArticleId><ArticleId IdType="pubmed">33615750</ArticleId></ArticleIdList></Reference><Reference><Citation>Chotpitayasunondh T., Fischer T.K., Heraud J., Hurt A.C., Monto A.S., Osterhaus A., Shu Y., Tam J.S. Influenza and COVID-19: What does co-existence mean? Influenza Other Respir. Viruses. 2021;15:407&#x2013;412. doi: 10.1111/irv.12824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12824</ArticleId><ArticleId IdType="pmc">PMC8051702</ArticleId><ArticleId IdType="pubmed">33128444</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S., Kr&#xfc;ger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.-H., Nitsche A., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271&#x2013;280.e8. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Weis W., Brown J.H., Cusack S., Paulson J.C., Skehel J.J., Wiley D.C. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature. 1988;333:426&#x2013;431. doi: 10.1038/333426a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/333426a0</ArticleId><ArticleId IdType="pubmed">3374584</ArticleId></ArticleIdList></Reference><Reference><Citation>Traylor Z.P., Aeffner F., Davis I.C. Influenza A H1N1 induces declines in alveolar gas exchange in mice consistent with rapid post-infection progression from acute lung injury to ARDS. Influenza Other Respir. Viruses. 2013;7:472&#x2013;479. doi: 10.1111/j.1750-2659.2012.00414.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-2659.2012.00414.x</ArticleId><ArticleId IdType="pmc">PMC3494753</ArticleId><ArticleId IdType="pubmed">22862736</ArticleId></ArticleIdList></Reference><Reference><Citation>Green I., Ashkenazi S., Merzon E., Vinker S., Golan-Cohen A. The association of previous influenza vaccination and coronavirus disease-2019. Hum. Vaccines Immunother. 2021;17:2169&#x2013;2175. doi: 10.1080/21645515.2020.1852010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2020.1852010</ArticleId><ArticleId IdType="pmc">PMC8189123</ArticleId><ArticleId IdType="pubmed">33377817</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilkington E.H., Suys E.J., Trevaskis N.L., Wheatley A.K., Zukancic D., Algarni A., Al-Wassiti H., Davis T.P., Pouton C.W., Kent S.J., et al. From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases. Acta Biomater. 2021;131:16&#x2013;40. doi: 10.1016/j.actbio.2021.06.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actbio.2021.06.023</ArticleId><ArticleId IdType="pmc">PMC8272596</ArticleId><ArticleId IdType="pubmed">34153512</ArticleId></ArticleIdList></Reference><Reference><Citation>Conlon A., Ashur C., Washer L., Eagle K.A., Hofmann Bowman M.A. Impact of the influenza vaccine on COVID-19 infection rates and severity. Am. J. Infect. Control. 2021;49:694&#x2013;700. doi: 10.1016/j.ajic.2021.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajic.2021.02.012</ArticleId><ArticleId IdType="pmc">PMC7899024</ArticleId><ArticleId IdType="pubmed">33631305</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Al-Aly Z. Nirmatrelvir and the Risk of Post-Acute Sequelae of COVID-19. medRxiv. 2022 doi: 10.1101/2022.11.03.22281783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.11.03.22281783</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>